Format

Send to:

Choose Destination
See comment in PubMed Commons below
World J Gastroenterol. 2012 May 28;18(20):2586-90. doi: 10.3748/wjg.v18.i20.2586.

Lamivudine treatment enabling right hepatectomy for hepatocellular carcinoma in decompensated cirrhosis.

Author information

  • 1First Department of Internal Medicine, Oita University, Oita 879-5593, Japan. hondak@oita-u.ac.jp

Abstract

A 69-year-old man was admitted to our hospital in October 2003, for further examination of two liver tumors. He was diagnosed with hepatocellular carcinoma (HCC) arising from decompensated hepatitis B virus (HBV)-related cirrhosis. Long-term lamivudine administration improved liver function dramatically despite repeated treatment for HCC. His Child-Pugh score was 9 points at start of lamivudine treatment, improving to 5 points after 1 year. His indocyanine green at 15 min after injection test score was 48% before lamivudine treatment, improving to 22% after 2 years and to 5% after 4 years. Radiofrequency ablation controlled the HCC foci and maintained his liver function. In April 2009, abdominal computed tomography revealed a tumor thrombus in the right portal vein. Since his indocyanine green test results had improved to less than 10%, we performed a right hepatectomy, which was successful. To our knowledge, there have been no documented reports of patients undergoing successful right hepatectomy for HCC arising from decompensated cirrhosis. The findings observed in our patient indicate the importance of nucleoside analogs for treating HBV-related HCC.

KEYWORDS:

Decompensated cirrhosis; Hepatectomy; Hepatitis B virus; Hepatocellular carcinoma; Lamivudine

PMID:
22654459
[PubMed - indexed for MEDLINE]
PMCID:
PMC3360460
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk